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Mutations in Leucine-rich repeat kinase 2 gene (LRRK2) are associated with familial and
sporadic Parkinson’s disease (PD). LRRK2 is a complex protein that consists of multiple
domains executing several functions, including GTP hydrolysis, kinase activity, and protein
binding. Robust evidence suggests that LRRK2 acts at the synaptic site as a molecular
hub connecting synaptic vesicles to cytoskeletal elements via a complex panel of
protein-protein interactions. Here we investigated the impact of pharmacological inhibition
of LRRK2 kinase activity on synaptic function. Acute treatment with LRRK2 inhibitors
reduced the frequency of spontaneous currents, the rate of synaptic vesicle trafficking
and the release of neurotransmitter from isolated synaptosomes. The investigation
of complementary models lacking LRRK2 expression allowed us to exclude potential
off-side effects of kinase inhibitors on synaptic functions. Next we studied whether
kinase inhibition affects LRRK2 heterologous interactions. We found that the binding
among LRRK2, presynaptic proteins and synaptic vesicles is affected by kinase inhibition.
Our results suggest that LRRK2 kinase activity influences synaptic vesicle release via
modulation of LRRK2 macro-molecular complex.
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INTRODUCTION
Parkinson’s disease (PD) is an age-related neurodegenerative dis-
ease affecting 2% of the population above 65-years and is clini-
cally characterized by bradykinesia, rigidity, and resting tremor.
The neuropathological hallmark of the disease is the progressive
loss of dopaminergic neurons in the substantia nigra (Moore et al.,
2005; Hardy et al., 2006). Although the majority of cases are idio-
pathic, mutations in the Leucine-rich repeat kinase 2 (LRRK2)
gene (PARK8; OMIM 609007) cause late-onset PD. LRRK2muta-
tions account for up to 13% of familial PD cases compatible
with dominant inheritance (Paisan-Ruiz et al., 2004; Zimprich
et al., 2004) and have been identified in 1–2% of sporadic PD
patients (Aasly et al., 2005; Berg et al., 2005). LRRK2 is a large
protein encompassing several functional domains including a
kinase domain with feature similar to mitogen activated protein
kinase kinase kinases (MAPKKK) and receptor-interacting pro-
tein kinases (RIPK) (Bosgraaf and Van Haastert, 2003; Guo et al.,
2006). Several single nucleotide variants have been identified in
LRRK2 (Brice, 2005). While only the common G2019S mutation,
located in the kinase domain, has been consistently associated
with increased kinase activity in vitro (West et al., 2005; Gloeckner
et al., 2006; Greggio et al., 2006), a recent study monitoring
LRRK2 autophosphorylation at Ser 1292 suggested that other
pathogenic mutants possess augmented activity in the cellular
context (Sheng et al., 2012). Up to now few LRRK2 substrates have
been identified in in vitro studies, but none has been convinc-
ingly proved in vivo, leaving the pathophysiological relevance of
the kinase activity unclear. Instead, several lines of evidence sug-
gest that kinase activity is linked to LRRK2 dimerization (Greggio
et al., 2008; Sen et al., 2009; Civiero et al., 2012) as well as sub-
cellular distribution (Berger et al., 2010) and regulates binding to
14-3-3 proteins (Nichols et al., 2010). Accumulating data corre-
late LRRK2 to synaptic functions. Several studies suggested that
LRRK2 is part of a protein complex that influences the trafficking
of synaptic vesicles belonging to the recycling pool (Shin et al.,
2008; Piccoli et al., 2011; Matta et al., 2012). The description
of synaptic phenotype in LRRK2 mutant models (Tong et al.,
2009; Migheli et al., 2013; Yun et al., 2013) further underlines the
tight link among LRRK2, synaptic vesicle trafficking and neuro-
transmitter release. In this study we investigated the functional
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impact of LRRK2 kinase activity on presynaptic function and we
determined functional properties of neurons upon LRRK2 phar-
macological inhibition. A combination of electrophysiological,
biochemical and imaging analyses suggested that LRRK2 inhibi-
tion impacts synaptic transmission acting on the organization of
LRRK2 macro-molecular complex at the presynaptic site.
MATERIALS AND METHODS
ANIMALS, NEURON CULTURES, AND DRUGS
Non-transgenic wild-type (WT) and LRRK2 knock-out (KO)
mice, back-crossed on a C57BL/6J strain, were obtained from
Mayo Clinic (Jacksonville, FL, USA) through a collaboration
with Prof. Matthew Farrer and Dr. Heather Melrose (Hinkle
et al., 2012). Animals were kept following guidelines of Ministry
of Education, Universities and Research (MIUR). Neuron cul-
tures were prepared from either mouse cortexes or hippocampi
obtained from embryonic day 15.5–16.5 mice (C57BL/6J).
High-density (750–1000 cells/mm2) and medium-density (150–
200 cells/mm2) neuron cultures were plated and grown as
described on 12-well plastic tissue culture plates (Iwaki; Bibby
Sterilin Staffordshire, UK) or on 12mm diameter coverslips put
into 24-well plastic tissue culture plates (Iwaki) (Piccoli et al.,
2007). IN-1 and GSK-2578215A compounds (Tocris Bioscience,
Bristol, UK) or DMSO were added to culture media at the
concentrations indicated through the text.
PLASMIDS AND PROTEIN PURIFICATION
N-terminal 3xFLAG and myc hLRRK2 full length (hereinafter
FLAG-LRRK2 and myc-LRRK2), N-terminal FLAG hLRRK2
A2106T (a kind gift of Prof. Dario Alessi, MRC, University of
Dundee), LRRK2 silencing and control viral constructs vectors
have been already described (Bauer et al., 2009; Nichols et al.,
2009; Civiero et al., 2012). FLAG-LRRK2 was purified via affinity
chromatography using FLAG-M2 agarose beads (Sigma Aldrich)
as previously described (Civiero et al., 2012) from HEK293T
cells transfected by lipofection using Lipofectamine 2000 (Life
Technologies Carlsbad, CA, USA) according to manufacturer’s
instructions. Viral particles were produced as in (Bauer et al.,
2009). Neurons were infected at DIV4 and processed when
indicated.
IMMUNO-PRECIPITATION AND ANTIBODIES
Immunoprecipitation was performed as described previously
(Onofri et al., 2007) using 25µl of settled prewashed pro-
tein G-Sepharose beads (GE-Healthcare, Freiburg, Germany) to
precipitate the immunocomplexes. NaCl 150mM, Tris 50mM
(pH 7.4), NP-40 (1% v/v), SDS (0.1% v/v) and protease and
phosphatase inhibitors extracts of Percoll-purified synaptosomes
obtained from rat cerebral cortex were incubated for 2 h at RT in
absence or in presence of IN- 1 (1µM) with anti-LRRK2 anti-
bodies (10µg/sample; MJFF C41-2 Abcam, Cambridge UK) or
a control rabbit IGg (10µg/sample; Sigma-Aldrich, St. Louis,
MO, USA). The eluted proteins were separated by SDS-PAGE,
transferred onto nitrocellulose membrane (GE-Healthcare) and
analyzed by western-blotting. Antibodies list includes rabbit anti
LRRK2 1:500 MJFF C41-2, rabbit anti LRRK2 P-Ser 935 UDD2
10(12) (Abcam), rabbit anti synapsin I 1:500 (Synaptic System,
Goettingen, Germany), mouse anti actin 1:1000, mouse anti
FLAG 1:1000, mouse anti myc 1:1000, mouse anti synaptophysin
1:1000 (Sigma-Aldrich St. Louis, MO, USA). The secondary
antibodies (HRP-conjugated anti-mouse, anti-rabbit) (BIORAD,
Hercules, CA, USA) were used in a ratio of 1:5000 coupled
with the ECL chemiluminescence detection system. Immunoblots
were quantified by densitometric analysis of the fluorograms
(Quantity One software, Bio-Rad) obtained in the linear range
of the emulsion response.
IN VITRO KINASE ASSAY
GST-LRRK2970−2527 (Life technologies) at the concentration of
30 nM were incubated with 500µM LRRKtide, 100µM 33P-ATP
(0.5µCi) in kinase reaction buffer consisting of 25mM Tris-
HCl (pH7.5), 5mM beta-glycerophosphate, 2mM dithiothreitol
(DTT), 0.1mM Na3VO4, 10mM MgCl2 and increasing concen-
trations of inhibitors at 30◦C for 1 h. Reactions were carried out
in triplicate and spotted onto P81 phosphocellulose. Following
different washing of phosphocellulose membranes with 75mM
phosphoric acid, 33P incorporation into LRRKtide was quantified
with Cyclone (Perkin Elmer, Alameda, CA, USA).
SIZE EXCLUSION CHROMATOGRAPHY
Cells transiently transfected with FLAG-LRRK2 wild-type were
solubilized in lysis buffer containing 20mM Tris-HCl pH 7.5,
150mM NaCl, 1mM EDTA, 1% Triton X-100, 2.5mM sodium
pyrophosphate, 1mM beta-glycerophosphate, 1mM NaVO4,
protease inhibitor cocktail (Sigma-Aldrich) and lysates were
cleared for 30min at 14,000 xg. When appropriate, proteins were
further purified via FLAG immunoprecipitation as described
above. Cleared lysates (0.5ml; 5mg total proteins) or purified
proteins (0.5ml; 1.3µg of purified protein) were injected and
separated on a Superose 6 10/300 column (GE Healthcare). The
column was preequilibrated with buffer (20mM Tris-HCl pH
7.5, 150mM NaCl and 0.07% Triton X-100) and used at a flow
rate of 0.5ml/min. Elution volumes of standards were 7.5ml
for Blue Dextran (V0), 11.5ml for hemocyanin from Carcinus
aestuarii (900 kDa), 12ml for thyreoglobin (669 kDa), 14ml for
ferritin (440 kDa). When appropriate, inhibitors (1µM IN-1 and
1µM GSK-2578215A) were applied for 90min before lysis and
kept throughout the following purification steps, including equi-
libration of chromatographic mobile phase. Chromatographic
fractions were analyzed by dot blot. One microliter of each frac-
tion from SEC was applied onto a nitrocellulose membrane.
The membrane was blocked with 10% (w/v) milk in TBS plus
0.1% Triton (TBS-T) for 1 h and subsequently incubated with
mouse monoclonal anti-Flag M2-peroxidase (Sigma-Aldrich).
Immunoreactive proteins were visualized using enhanced chemi-
luminescence plus (ECL plus, GE Healthcare).
SYNAPTIC VESICLE PURIFICATION AND LRRK2 BINDING ASSAYS
Synaptic vesicles (SV) were obtained from rats by homogeniza-
tion of the isolated forebrains and finally purified through the
step of controlled-pore glass (CPG) chromatography (Huttner
et al., 1983). After elution, purified SV were centrifuged for 2 h
at 175,000 × g and resuspended at a protein concentration of 1–
2mg/ml in 0.3M glycine, 5mMHEPES, 0.02% sodium azide, pH
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7.4 (glycine buffer). Protein concentrations were determined by
the Bradford or BCA assays. SDS-PAGE was performed according
to Laemmli (1970). For the dissociation of endogenously bound
LRRK2 purified SV (40µg/sample) were incubated for 1 h at
30◦C with or without IN-1 (1µM) in glycine buffer plus 30mM
NaCl, 25mM Tris/HCl, 2mM DTT, 10mM MgCl2 protease and
phosphatase inhibitors. After the incubation, LRRK2 bound to
SV were separated by soluble LRRK2 by high-speed centrifuga-
tion (400,000 × g for 45min) (Messa et al., 2010). Aliquots of
the resuspended pellets were subjected to SDS–PAGE and subse-
quent Western blotting with anti LRRK2 MJFF C41-2 (Abcam)
antibody. The recovery of SV, used to correct the amounts of
LRRK2 bound to SV, was determined by Western blotting with
anti-synaptophysin antibody (kind gift of Prof. Paul Greengard
The Rockefeller University New York USA). The binding of
purified FLAG-LRRK2 to native SV was performed like below.
SV (10µg/sample) were incubated for 1 h at 0◦C with FLAG-
LRRK2 (50 nM) in glycine buffer plus 30mM NaCl, 25mM
Tris/HCl, 2mM DTT, 10mM MgCl2 protease and phosphatase
inhibitors and 1.0µg/ml bovine serum albumin in absence or
in presence of IN-1 (1µM). After incubation, SV-bound FLAG-
LRRK2 was separated by high-speed centrifugation (400,000 g
for 45min). Aliquots of the resuspended pellets were subjected
to immunoblotting with anti-FLAG (Sigma-Aldrich) antibodies.
The recovery of SV was determinated like above.
EXO-ENDOCYTOTIC ASSAY
The endocytosis assay to monitor SV recycling was performed
using rabbit polyclonal antibodies directed against the intrav-
esicular domain of synaptotagmin1 (Synaptic System), applied
for 5min if not indicated otherwise at RT on the cultures, as
described previously (Matteoli et al., 1992). Incubations with
the antibody (1:400) were performed in Tyrode solution con-
taining 124mM NaCl, 5mM KCl, 2mM MgCl2, 30mM glucose,
25mM HEPES, pH 7.4 and 2mM CaCl2. After fixation and per-
meabilization, a synaptophysin counter staining with mouse anti
synaptophysin, 1:400 (Sigma-Aldrich) visualized the totality of
SV. Acquired images were processed and quantitatively analyzed
with ImageJ software as previously described (Verderio et al.,
1999). Briefly, GFP positive processes were manually tracked and
the number of synaptotagmin and synaptophysin positive clus-
ters and synaptophysin positive clusters present in the region of
interest were automatically counted.
NEUROTRANSMITTER RELEASE
Synaptosome were isolated from cerebral cortex (fronto-temporal
areas) as described previously (Marti et al., 2003; Mela et al.,
2004). The synaptosomal pellet was resuspended in oxygenated
(95% O2, 5% CO2) Krebs solution (mM: NaCl 118.5, KCl 4.7,
CaCl2 1.2, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25, glucose 10).
One millilitre aliquot of the suspension (∼0.35mg protein) was
slowly injected into nylon syringe filters (outer diameter 13mm,
0.45µMpore size, internal volume of about 100µl; Teknokroma,
Barcelona, Spain) connected to a peristaltic pump. Filters were
maintained at 36.5◦C in a thermostatic bath and superfused
at a flow rate of 0.4ml/min with a preoxygenated Krebs solu-
tion. Under the superfusion conditions adopted in the present
study, the fast and continuous removal of endogenous substances
released by nerve terminals rules out that endogenous glutamate
is uptaken by glutamate transporters, or even activates autore-
ceptors. Sample collection (every 3min) was initiated after a
20min period of filter washout. The effect of IN-1 was evaluated
on both spontaneous efflux and K+-stimulated neurotransmitter
outflow. IN-1 (3µM) was added to the perfusion medium 9min
before a 90 s pulse of 15mM KCl, and maintained until the end
of the experiment. In other experiments purified synaptosomes
were prepared on Percoll gradients (Sigma-Aldrich) and incu-
bated at 37◦C for 15min in presence of 0.03µM [3H]D-aspartate
(Marte et al., 2010). A 90 s period of depolarization was applied
at t = 39min of superfusion with 15mMKCl, substituting for an
equimolar concentration of NaCl. IN-1 1µM was added 9min
before depolarization. Fractions collected and superfused synap-
tosomes were counted for radioactivity by liquid scintillation
counting. The efflux of radioactivity in each fraction has been
expressed as a percentage of the total radioactivity present in
synaptosomes at the onset of the fraction collected (fractional
rate). Depolarization-evoked neurotransmitter overflow was cal-
culated by subtracting the transmitter content of the two 3-min
fractions, representing the basal release, from that in the two
3-min fractions collected during and after the depolarization
pulse.
SLICE ELECTROPHYSIOLOGY
C57Bl/6J mice were anesthetized in a chamber saturated with
chloroform and then decapitated. The brain was rapidly removed
and placed in an ice-cold solution containing 220mM sucrose,
2mM KCl, 1.3mM NaH2PO4, 12mM MgSO4, 0.2mM CaCl2,
10mM glucose, 2.6mM NaHCO3 (pH 7.3, equilibrated with
95% O2 and 5% CO2). Coronal hippocampal slices (thickness,
250–300µm) were prepared with a vibratome VT1000 S (Leica,
Wetzlar Germany) and then incubated first for 40min at 36◦C
and then for 30min at room temperature in artificial CSF (aCSF),
consisting of (in mM) 125 NaCl, 2.5 KCl, 1.25 NaH2PO4, 1mM
MgCl2, 2mM CaCl2, 25mM glucose, and 26mM NaHCO3 (pH
7.3, equilibrated with 95% O2 and 5% CO2). Slices were then
divided into 2 experimental groups: the first one was the control
group and the second one was the group of slices incubated with
the inhibitor 1 at concentration of 2µMfor at least 2 h. Slices were
transferred to a recording chamber perfused with aCSF, where
the concentration of CaCl2 was increased to 4mM and MgCl2
decreased to 0.5mM, due to the low frequency of miniature exci-
tatory post-synaptic currents (mEPSCs) in CA1 hippocampus,
at a rate of ∼2ml/min and at 38◦C. Whole-cell patch-clamp
electrophysiological recordings were performed with an Axon
Multiclamp 700 B amplifier (Molecular devices, Sunnyvale, CA
USA) and using an infrared-differential interference contrast
microscope. Patch microelectrodes (borosilicate capillaries with
a filament and an outer diameter of 1.5µm; Sutter Instruments,
Novato, CA USA) were prepared with a four-step horizontal
puller (Sutter Instruments) and had a resistance of 3–5M.
mEPSCs were recorded at a holding potential of −65mV
with an internal solution containing: 126mMK-gluconate, 4mM
NaCl, 1mM EGTA, 1mM MgSO4, 0.5mM CaCl2, 3mM ATP
(magnesium salt), 0.1mM GTP mM (sodium salt), 10mM
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glucose, 10mM HEPES (pH adjusted to 7.3 with KOH). Access
resistance was between 10 and 20M; if it changed by>20% dur-
ing the recording, the recording was discarded. All glutamatergic
currents were recorded in the presence of bicuculline (20µM)
in the external solution, to block the GABAergic transmission,
and lidocaine (500µM), to block the action potentials onset.
Currents through the patch-clamp amplifier were filtered at 2 kHz
and digitized at 20 kHz using Clampex 10.1 Software (Molecular
Devices). Analysis was performed offline with Clampfit 10.1
software (Molecular Devices).
ELECTROPHYSIOLOGICAL RECORDINGS OF CULTURED NEURONS
Whole-cell voltage clamp recordings were performed using a
MultiClamp 700 A amplifier (Molecular devices) coupled to
a pCLAMP 10 Software (Molecular Devices), and using an
inverted Axiovert 200 microscope (Zeiss, Oberkochen Germany).
Patch electrodes, fabricated from thick borosilicate glasses (Sutter
Instruments) were pulled and fire-polished to a final resistance of
3–5M using a two-stage puller (Narishige, Japan). Experiments
were performed at room temperature (20–25◦C) in the exter-
nal control solution KRH (125mM NaCl, 5mM KCl, 1.2mM
MgSO4, 1.2mM KH2PO, 2mM CaCl2, 6mM D-glucose, and
25mM HEPES/NaOH, pH 7.4). The age of the patched neurons
ranged between 13 and 16DIV. Recordings were performed keep-
ing neurons at holding potential of -70mV, in the presence of
1µM TTX and using the following internal solution (Potassium
Gluconate—KGluc): 130mM KGluc, 10mM KCl, 1mM EGTA,
10mM HEPES, 2mM MgCl2, 4mM MgATP, 0.3mM Tris-GTP
(pH 7.4, adjusted with KOH). Traces were acquired at 10 kHz
and lowpass filtered at 4 kHz. Recordings with either leak currents
>300 pA or series resistance>20Mwere discarded. Series resis-
tance was monitored during experiments and recordings with
changes over 20% control during experiments were also dis-
carded. mEPSC traces were analyzed usingMiniAnalysis Program
(Synaptosoft Decatur, GA USA) with a threshold of 10 pA. Only
events exceeding the baseline noise by >2 SDs were considered.
The mean mEPSC frequency for CTRL neurons was 1.23646 ±
0.13746Hz (mean ± SE).
STATISTICAL ANALYSIS
All data are expressed as mean ± standard error of the mean
(SE). Data were analyzed with an unpaired Student’s t-test (two
groups) or ANOVA followed by Dunn’s post-hoc test (more than
two groups). The indication of number of experiment (n) and
level of significance (p) are indicated throughout the text.
RESULTS
LRRK2 KINASE INHIBITION IMPAIRS SYNAPTIC TRANSMISSION
We previously demonstrated that LRRK2 controls synaptic trans-
mission acting as a presynaptic scaffold (Piccoli et al., 2011).
Given that LRRK2 possesses an active kinase domain, we inves-
tigated the impact of LRRK2 kinase inhibition on synaptic activ-
ity. We modulated LRRK2 kinase activity taking advantage of
two potent LRRK2 inhibitors, IN-1 (Deng et al., 2011) and
GSK-2578215A (Reith et al., 2012) (hereinafter GSK). These
two molecules proved to inhibit LRRK2 kinase activity when
tested by in vitro assays where GST-LRRKtide was offered to
recombinant LRRK2 (Figures A1A–C). We confirmed IN-1 and
GSK efficacy on acute hippocampal slices treated with IN-1
and GSK (both 1µM, 2 h) before solubilization and western-
blotting. LRRK2 kinase activity, indirectly monitored by P-Ser
935 level, was clearly impaired upon incubation of slices with
IN-1 and GSK (Figures 1A,B). Thus, we monitored the effect
of kinase inhibition on presynaptic SV recycling by exposing
living culture to rabbit polyclonal antibodies directed against
the intravesicular domain of synaptotagmin1, which are inter-
nalized inside the vesicle lumen upon SV recycling (Matteoli
et al., 1992). Cortical cultures were infected at DIV4 with con-
trol viruses co-expressing GFP to track neuronal processes and
assayed at DIV14. Prior to these assays, primary cultures were
treated with vehicle (DMSO) or IN-1 or GSK (both 2µM for
2 h). Vesicles within GFP positive processes were then moni-
tored via laser confocal microscopy. The vesicles appeared as
clusters either synaptotagmin and synaptophysin positive (i.e.,
cycling vesicles) or only synaptophysin positive (Figure 2A). The
analysis showed that LRRK2 inhibition via either IN-1 or GSK
induced a significant decrease in the number of synaptotagmin
and synaptophysin positive clusters (Figure 2B). The total num-
ber of synaptic contacts, however, remained unaltered despite any
pharmacological treatments (Figure 2C). A number of off-targets
has been described for LRRK2 IN-1, including ERK5 (Luerman
et al., 2014). Thus, in order to determine if the effect reported
was specifically related to LRRK2 kinase inhibition, we quanti-
fied SV recycling rate in cultures infected at DIV4 with viruses
expressing LRRK2 silencing constructs, siRNA LRRK2 (Bauer
et al., 2009; Piccoli et al., 2011). As previously reported, LRRK2
silencing was associated to an increase in synaptotagmin uptake
(Piccoli et al., 2011). Interestingly, we did not measure any sig-
nificant alteration of SV recycling rate or number of synaptic
contact upon IN-1 or GSK treatment in LRRK2 silenced culture
(Figures 2D,E). These results likely exclude that the effect seen
on SV trafficking arises from substantial off target effect of IN-
1 or GSK. Furthermore, our data suggest that IN-1 and GSK
have similar efficacy in terms of kinase inhibition and impact
on SV trafficking. Based on the equivalent behavior of the two
inhibitors, in the subsequent functional assays we focused mainly
FIGURE 1 | IN-1 and GSK inhibit LRRK2 activity ex-vivo. (A) Acute
hippocampal slices were incubated in regular aCSF (NT) or in aCSF + IN-1
(IN-1) or GSK (GSK) both 1µM for 2 h at RT. Slices were then solubilized
and assayed by western blotting for P-Ser 935, LRRK2 and actin level.
(B) The graph reports P-Ser 935 level, normalized on LRRK2 level and
calculated as fold over not treated sample. Data are expressed as mean ±
s.e.m; ∗p < 0.01 vs. not treated sample, n = 4, ANOVA followed by Dunn’s
post-hoc test.
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FIGURE 2 | LRRK2 kinase inhibition impairs SV trafficking. (A) The
exo-endocytotic assay was performed on cortical neurons infected at DIV4
with virus expressing control siRNA and GFP and left untreated (NT) or
incubated with IN-1 or GKS compound (both 2µM for 2 h) before being
tested at DIV14. Cycling SV appear as synaptotagmin (s-tagmin) positive
clusters along neuron processes. Total SV pool was revealed by staining
with anti-synaptophysin antibodies upon fixation and permeabilization.
Images show signals acquired for synaptotagmin, synaptophysin and their
superimposition plus GFP (merge). (B) The percentage of s-tagmin and
s-physin positive clusters within the totality of s-physin positive clusters
reflects the pool of cycling vesicles. (C) Total number of SV pools was not
altered by treatment with IN-1 and GSK compound. The graph reports
number of synaptophysin-positive clusters per 10µm of GFP-positive
process. (D) Similar experiments were performed on cortical neurons
infected on DIV4 with viruses expressing LRRK2 siRNA and GFP. In LRRK2
down-regulated culture SV cycling is not affected upon treatment with IN-1
and GSK compound (both 2µM for 2 h). (E) Total number of SV pools was
not altered by treatment with IN-1 and GSK compound. The graph reports
number of synaptophysin-positive clusters per 10µm of GFP-positive
process. Data are expressed as mean ± s.e.m.; ∗p < 0.05 vs. not treated,
n = 20, ANOVA followed by Dunn’s post-hoc test. Panel size is 35 × 5µm.
on IN-1. Given the impact of LRRK2 inhibition on SV traffick-
ing, we next investigated the effect on IN-1 on neurotransmitter
release. To this aim we measured glutamate release from isolated
synaptosomes upon IN-1 treatment in either basal or stimu-
lated condition (Figure 3A). A pulse of 15mM K+ caused an
approximate three-fold, transient elevation of glutamate levels.
IN-1 (3µM) did not affect spontaneous glutamate efflux, but
inhibited the K+-evoked glutamate overflow by about 60%. In
FIGURE 3 | IN-1 impairs neurotransmitter release from isolated
synaptosome. (A) Synaptosomes obtained from the cerebral
(fronto-temporal) cortex of LRRK2 WT mice were perfused with Krebs
solution, and stimulated with a 90 s pulse of 15mM KCl. IN-1 (3µM) was
perfused 9min before KCl and maintained until the end of experiment. IN-1
reduced K+-evoked glutamate overflow. Data are means ± s.e.m. of 5–6
determinations per group, and are expressed as absolute glutamate
concentrations in the superfusate (in nM) or K+-evoked glutamate overflow
(in pmol/mg protein/min; insets). (B) Similar experiments were executed on
cortical synaptosome obtained from LRRK2 KO mice. IN-1 (3µM) failed to
impair K+-evoked glutamate overflow. Statistical analysis was performed on
overflow values by the Student t-test for unpaired data. ∗∗p < 0.01 different
from KCl alone.
a complementary approach, we measured the basal and evoked
(15mM K+) release of [3H]D-aspartate in presence or not of
IN-1 (1µM). Also in this model, IN-1 impaired the K+ evoked
release by about 35% (calculated as fraction of overflow and
expressed as mean ± s.e.m.: K+ alone = 1.4 ± 0.01 K+ + IN-
1 = 0.9 ± 0.01, p < 0.01, n = 7, Student’s t-test). To exclude
potential off target effect of IN-1, we studied glutamate release
in synaptosomes obtained from LRRK2 KO mice (Figure 3B).
Spontaneous and K+-evoked glutamate efflux was not different
between the two genotypes. However, IN-1 (3µM) did not signif-
icantly influence the K+-evoked glutamate release in LRRK2 KO
mice. Robust evidence correlates synapsin I to the mobilization
of SV and release of neurotransmitter (Orenbuch et al., 2012).
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Thus, we verified whether the lack of effect of IN-1 on glutamate
release we reported in LRRK2 KOmice could arise from disturbed
synapsin I level. Western blotting analysis of synaptosome from
wild-type and LRRK2 KO mice did not shown any significant
difference (Figure A1D). This evidence indicates that the impair-
ment in neurotransmitter release arises from a specific effect of
IN-1 on LRRK2. Given the impact of LRRK2 kinase inhibition on
presynaptic functions, we next evaluated the functional outcome
of LRRK2 inhibition in terms of neuronal activity. To this aim, we
studied the electrophysiological properties in two different neu-
ronal models, namely acute hippocampal slices and hippocampal
cultures. First we exposed acute hippocampal slices obtained
from wild-type mice at P21-22 to IN-1 2µM for 2 h before elec-
trophysiological recording in CA1 region. We detected a clear
reduction in miniature excitatory responses (mEPSCs) frequency
in the absence of any change in amplitude, rise, or decay time
upon acute IN-1 treatment (Figures 4A–F). In order to validate
the impact of LRRK2 inhibition, we measured the electrophysio-
logical properties of primary hippocampal neurons treated with
IN-1, 2µM for 2 h. Our experiments demonstrated that acute IN-
1 treatment reduces mEPSC frequency but not amplitude, rise
or decay time (Figures 4G–K). Similar results were obtained by
treating cells with GSK (1µM, 2 h; NT = 1 ± 0.21, GSK = 0.5 ±
0.09, p = 0.057, n = 6; values represent frequency normalized on
FIGURE 4 | IN-1 influences mEPSC frequency. (A) Representative traces of
mEPSCs from CA1 pyramidal neurons of hippocampal slices incubated in
regular aCSF (NT) or in aCSF + IN-1 (2µM) for at least 2 h (IN-1). (B) A single
mEPSC is shown. Quantification of mEPSCs basal properties reveal changes
in current frequency (C) but not amplitude (D), area (E) and decay (F). Data
are expressed as mean ± s.e.m.; ∗∗p < 0.01 vs. NT, Student’s t-test, n = 15.
(G) Representative traces of mEPSCs from hippocampal culture at DIV12-13
under control condition (NT) or after incubation with IN-1 (2µM) for 2 h. IN-1
pretreatment reduces mEPSC frequency (H), but not amplitude (I), rise (J) or
decay (K) time. Data were normalized on not treated condition and expressed
as mean ± s.e.m.; ∗p < 0.05 vs. not treated, n = 14, ANOVA followed by
Dunn’s post-hoc test.
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untreated cultures and expressed as mean ± s.e.m.). These exper-
iments indicate that the pharmacological inhibition of LRRK2
kinase activity reduces synaptic transmission affecting SV recy-
cling and thus neurotransmitter release.
KINASE ACTIVITY CONTROLS LRRK2 BINDING PROPERTIES
Independent studies demonstrated that LRRK2 exists in multiple
oligomeric state: kinase-active dimer (Deng et al., 2008; Greggio
et al., 2008; Klein et al., 2009) and monomers or oligomers
mainly inactive (Sen et al., 2009). Thus, we asked whether LRRK2
kinase inhibition might influence LRRK2 oligomeric state. First
we explored whether kinase inhibition affects LRRK2 homolo-
gous interaction by evaluating the extent of LRRK2 dimerization
in presence of IN-1. To this aim we co-expressed FLAG-LRRK2
and myc-LRRK2 in HEK293T cells; we subsequently treated the
cell with IN-1 (2 h, 1µM) and eventually we immobilized LRRK2
on FLAG-M2 beads. After elution, we measured the recovery of
FLAG and myc LRRK2 by immunoblotting with specific anti tag
antibodies (Figure 5A). We found that IN-1 treatment does not
significantly affect the amount of myc LRRK2 co-precipitating
with FLAG-LRRK2 (Figure 5B). To further explore the impact of
kinase inhibition on LRRK2 oligomerization, we performed size
exclusion chromatography (SEC) experiments on FLAG-LRRK2
proteins purified from untreated cells and then incubated with
IN-1 (1µM, 90min). As shown in Figures 5C,D, the elution
profile of purified LRRK2 is onlymarginally affected by IN-1 inhi-
bition. We obtained comparable results incubating FLAG-LRRK2
with GSK (1µM, 90min, data not shown). These data suggest
that kinase inhibitionminimally impacts LRRK2 oligomeric state.
Next, we asked whether kinase inhibition engages LRRK2 in dif-
ferential heterologous interactions. We have previously demon-
strated that LRRK2 interacts with a panel of proteins, including
actin (Piccoli et al., 2011). Thus, we analyzed by SEC the elu-
tion profile of FLAG-LRRK2 and actin in lysates extracted from
cells treated with IN-1 (1µM, 90min). Interestingly, we observed
that IN-1 shifted both LRRK2 and actin toward higher molec-
ular weight forms and that the two elution profiles partially
overlap (Figures 6A,B). This outcome might be consistent with
the possibility that LRRK2 forms higher molecular weight com-
plexes with actin upon IN-1 binding. To further substantiate
this hypothesis we over-expressed FLAG-LRRK2 A2016T, an arti-
ficial variant unable to bind IN-1, in HEK293T cells (Nichols
et al., 2009; Deng et al., 2011). When we analyzed by SEC the
elution profile of FLAG-LRRK2 A2016T and actin in lysates
extracted from cells treated with IN-1 (2 h, 1µM), we observed
that IN-1 failed to shift either LRRK2 or actin elution pro-
files (Figures 6C,D). All together these data strongly suggest that
kinase inhibition induces the formation of high-molecular weight
complexes including LRRK2 and its interacting partners. To fur-
ther explore this hypothesis, we asked whether LRRK2 inhibition
might affect LRRK2 affinity toward SV associated proteins such as
synapsin I and actin. To this aim we immunoprecipitated LRRK2
with anti-LRRK2 antibodies [MJFF C41-2] using purified synap-
tosomes treated with IN-1 (1µM) during the assay as protein
source. We found that the binding of LRRK2 to synapsin I and
actin increased in presence of IN-1 (Figures 7A,B). Given the
effects of kinase inhibition on LRRK2 binding features, we first
FIGURE 5 | IN-1 does not influence LRRK2 dimerization. (A) HEK293T
cells expressing both myc and FLAG LRRK2 were treated or not with IN-1
(2µM for 2 h), solubilized and processed for FLAG immunopurification. We
evaluated the extent of LRRK2 homodimerization by measuring the amount
of myc LRRK2 co-precipitating with FLAG LRRK2 (B) The graph reports the
amount of FLAG and myc LRRK2 recovered in FLAG immunoprecipitates
upon IN-1 incubation. Data were calculated as fraction of untreated sample
and expressed as mean ± s.e.m. (n = 4). (C) Full-length LRRK2 purified by
Flag immunoaffinity from untreated HEK293T cells was separated by size
exclusion chromatography (SEC) and subsequently treated or not with IN-1
(1µM, 90min on ice). (D) The intensity of each dot (fraction) is normalized
by the integrated intensities. Column void volume is 7.5ml.
investigated if LRRK2 binds to SV and, next, if kinase inhibition
disturbs LRRK2 and synapsin I binding to SV. To this aim we
incubated native purified SV (in the range of 40µg/sample) under
phosphorylation permissive conditions or in the presence of IN-
1 (1µM, 1 h). After incubation, we recovered SV by high speed
centrifugation and determined the amounts of bound LRRK2
and synapsin I by immunoblotting. The SV recovery in the pel-
let was evaluated based on synaptophysin immunoreactivity. We
found that LRRK2 binds SV and that this interaction is signifi-
cantly decreased in the presence of IN-1 while synapsin I binding
to SV was unaffected by IN-1 (Figures 7C,D). As a complemen-
tary approach we analyzed the impact of IN-1 (1µM, 1 h) on
the interaction between SV and exogenous recombinant FLAG-
LRRK2 (Figure A1C). After incubation, we separated SV-bound
LRRK2 by high-speed centrifugation and evaluated the recov-
ery of SV and bound LRRK2 and synapsin I in the pellet by
immunoblotting. Our data showed that IN-1 significantly reduces
exogenous LRRK2 binding to SV while the yield of SV-bound
synapsin I remains unaltered (Figures 7E,F). This evidence sug-
gests that kinase inhibition interferes with the macro-molecular
complex bound to LRRK2 at the presynaptic site.
Frontiers in Molecular Neuroscience www.frontiersin.org May 2014 | Volume 7 | Article 49 | 7
Cirnaru et al. LRRK2 at the presynaptic site
FIGURE 6 | IN-1 alters LRRK2 macromolecular complex. (A) HEK293T
cells expressing FLAG-LRRK2 wild-type were treated or not with IN-1
(1µM, 90min), solubilized and then separated by SEC. FLAG-LRRK2 and
actin were revealed by western-blotting of fractions spotted on
nitrocellulose. (B) The intensity of each dot (fraction) is normalized by the
integrated intensities. (C) HEK293T cells expressing FLAG-LRRK2 A2016T
were treated or not with IN-1 (1µM, 90min), solubilized and then separated
by SEC. LRRK2 and actin were revealed by western-blotting of fractions
spotted on nitrocellulose. (D) The intensity of each dot (fraction) is
normalized by the integrated intensities.
DISCUSSION
Our previous observations provided evidence that LRRK2 exe-
cutes critical functions at the presynaptic site; given its relative
position as an integral part of a presynaptic protein network,
LRRK2 may serve as a molecular hub coordinating both the stor-
age and the mobilization of SV driven by activity (Piccoli et al.,
2011, 2014). Recent work has clarified that LRRK2 controls SV
in the ready releasable pool via inhibitory phosphorylation of the
SNAP-25 interacting protein Snapin (Yun et al., 2013). The evi-
dence reported here adds one more level of complexity: the impli-
cation of LRRK2 kinase activity within synaptic functions. As wild
type LRRK2 is characterized by a low kinase activity (MacLeod
et al., 2006), it might be argued that physiologically LRRK2
acts as a scaffold protein and its kinase activity mainly regulates
its macro-molecular organization. In fact, several independent
FIGURE 7 | IN-1 modifies LRRK2 binding properties. (A) Extracts of
purified cortical synaptosomes were incubated with anti-LRRK2 antibodies
or rabbit IgG in absence (not treated) or in presence of IN-1 (IN-1, 1µM 2h).
The immunocomplexes were sedimented with protein G-Sepharose and
the samples were resolved by SDS-PAGE and analyzed by immunoblotting
with anti synapsin I, anti actin and anti LRRK2 antibodies. (B) Quantification
of IN-1 effect on LRRK2 interaction with synapsin I, actin and LRRK2 itself.
Results are calculated as percent of respective controls (not treated
sample) and expressed as mean ± s.e.m. (∗P < 0.05, n = 4, Student’s
t-test vs. not treated sample). (C) purified native synaptic vesicles (SV;
40µg/sample) were incubated in the absence (NT) or presence of IN-1
(IN-1, 1µM 2h). After incubation, SV were recovered by high speed
centrifugation and the residual amounts of endogenous LRRK2 bound to
SV were determined by immunoblotting with anti-LRRK2 antibodies. The
recovery of SV in the pellet was evaluated based on synaptophysin
immunoreactivity. (D) LRRK2 recovery in the SV pellet was calculated as
the percentage of the not treated sample and shown as mean ± s.e.m.
(∗P < 0.05, n = 8, Student’s t-test vs. relative control). (E) Purified
FLAG-LRRK2 was incubated with SV (10µg protein/sample) in presence or
absence (NT) of IN-1 (IN-1, 1µM 2h). SV-bound FLAG-LRRK2 was
separated from free FLAG-LRRK2 by high-speed centrifugation and
quantified by immunoblotting with anti-FLAG antibody. The recovery of SV
in the pellet was evaluated based on synaptophysin immunoreactivity.
(F) The binding of FLAG-LRRK2 to SV was calculated as the percentage of
total FLAG-LRRK2 and expressed as mean ± s.e.m. ∗p < 0.05; Student’s
t-test vs. relative control.
studies have revealed that LRRK2 exists in different forms in
equilibrium, namely monomer, dimer and oligomer, being the
dimer the predominant status under native conditions (Sen et al.,
2009; but see Ito and Iwatsubo, 2012). Interestingly, PD associ-
ated LRRK2 mutations disturb both LRRK2 dimerization (Sen
et al., 2009) and ternary complex formation (Nichols et al., 2010).
Furthermore, acute treatment with IN-1 induces the aggregation
of ectopic LRRK2 expressed in heterologous cell lines and inter-
feres with 14-3-3 binding (Deng et al., 2011). Our hypothesis is
that kinase inhibition triggers the formation of high molecular
weight complexes encompassing LRRK2 and LRRK2 interacting
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proteins. These phenomena might affect LRRK2 function at the
presynaptic site. Accordingly, we described that kinase inhibition
reduces LRRK2 binding to SV and at the same time increases
LRRK2 affinity toward actin and synapsin I. As suggested by
the SEC analysis of LRRK2 expression in heterologous lines,
we can speculate that kinase inhibition induces the formation
of LRRK2 high molecular weight complex also within neuronal
cells. Such complex might act as dominant-negative on synap-
tic function. In fact it might not only sequester LRRK2 but also
free actin and synapsin I, making them unavailable for physi-
ological binding to SV (Figure 8). Indeed we did not report a
clear reduction of synapsin I bound to SV upon IN-1 incuba-
tion or in presence of exogenous FLAG-LRRK2. This lack of an
effect could arise from the design of our experimental setup. In
fact we treated with IN-1 and/or FLAG-LRRK2 purified SV iso-
lated from their cellular context and incubated in artificial buffer.
LRRK2, synapsin I and actin regulate SV mobility from intra-
bouton pool to membrane where eventually SV fuse (Greengard
et al., 1993; Piccoli et al., 2011; Orenbuch et al., 2012). Given
the pivotal role of these three proteins during SV cycle and the
biochemical consequences of kinase inhibition on the stability
of LRRK2 binding with actin and synapsin I on one side and
with SV on the other, not surprisingly kinase inhibition impairs
proper SV cycling, reduces neurotransmitter release and, even-
tually, decreases synaptic activity. It remains unclear how kinase
activity can interfere with LRRK2 biochemical features. In partic-
ular, kinase inhibition might modulate LRRK2: 1) by reducing cis
or trans homo-phosphorylation thus affecting homodimerization
and/or 2) by impairing binding of LRRK2 interacting proteins
and/or 3) by abolishing phosphorylation of LRRK2 substrates
themselves involved in regulating LRRK2 macro-molecular com-
plex. While our studies do not address the third hypothesis, our
present work favors the possibility that kinase activity drives the
organization of LRRK2 macro-molecular complex. In fact, in our
hands LRRK2 kinase inhibition does not have a major effect on
LRRK2 dimerization but instead increases affinity toward inter-
acting partners. Furthermore, while we executed a number of
experiments in intact cells where potential LRRK2 interactors
as well as signaling machinery up or down stream to LRRK2
kinase activity might be present and functional, we addressed
the effect of kinase inhibitors also on isolated protein, i.e., puri-
fied LRRK2 extrapolated from its cellular context. In particular,
we reported that upon IN-1 incubation purified LRRK2 binds
less efficiently SV. Thus, a fourth intriguing hypothesis is that
the binding itself of IN-1 affects LRRK2 properties. A recent
observation suggested that IN-1 binding into the activation seg-
ment within kinase domain induces a wide-spread conforma-
tional change (Gillardon et al., 2013). Thus, it is possible that
the structural stress consequent to IN-1 binding slightly mod-
ifies LRRK2 folding and thus impairs LRRK2 binding to SV.
Given that our SEC analysis of isolated LRRK2 failed to reveal
any significant effect of IN-1, we predict such effect to be minor
or at least not able to robustly perturb LRRK2 oligomerization.
Although further studies are indeed required to fully dissect these
different hypothesis, overall our data indicate that LRRK2 func-
tion at the synaptic site depends on kinase regulation of LRRK2
macro-molecular organization. This might play a critical role
FIGURE 8 | Kinase activity controls LRRK2 molecular complex at the
synaptic site. (A) LRRK2 binds SV and regulates thier trafficking via
interaction with a panel of presynaptic proteins, including synapsin I,
syntaxin 1, SNAP-25, VAMP, and actin (see also Piccoli et al., 2011, 2014).
(B) Kinase inhibition detaches LRRK2 from SV and might induce the
formation of high-molecular weight complex including LRRK2, synapsin I
and actin. Such complex might sequester LRRK2, synapsin I and actin thus
hampering their function within SV cycle.
also in PD pathogenesis. In fact severe synaptic defects have
been reported in different models expressing kinase hyper-active
LRRK2 (reviewed in Belluzzi et al., 2012). In particular, G2019S
transgenic mice display an altered striatal DA release (Li et al.,
2010; Melrose et al., 2010) and the overexpression of mutant
G2019S influences SV trafficking rates (Shin et al., 2008; Yun
et al., 2013). Thus, synaptic activity might arise as a key path-
way affected by LRRK2 mutation. Being G2019S predicted as a
gain-of-function mutation, huge effort has been spent to develop
specific LRRK2 inhibitors. However, the side effect on kidney
described upon chronic treatment with LRRK2 inhibitor (Herzig
et al., 2011) together with the functional implication of LRRK2
endogenous kinase activity here described, suggest that other
therapeutic strategies might result necessary. Our work suggests
that the regulation of LRRK2 complex is a crucial molecular
actor implicated in LRRK2 physiological function and demon-
strate the necessity to tackle LRRK2 biology beyond its kinase
activity.
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APPENDIX
FIGURE A1 | IN-1 and GSK inhibit LRRK2 activity in vitro.
(A) Recombinant GST-LRRK2970−2527 was incubated with increasing
concentrations of LRRK2 inhibitors IN-1 or GSK in the presence of
500µM LRRKtide and 100µM ATP (0.5 µCi 33P-ATP). Reactions
were spotted onto P81 phosphocellulose paper and LRRKtide
radioactivity quantified by phosphoimaging scanner. (B) Dose-
response curves and calculation of IC50 values indicates that both
inhibitors are active against LRRK2 but at different potencies (n = 6
replicates, from 2 independent set of experiments). (C) Full length
FLAG-LRRK2 purified from transfected HEK293T cells and
GST-LRRK2970−2527 were resolved on SDS-PAGE and visualized via
coomassie staining. (D) Western-blotting analysis of synaptosome
purified from wild-type and LRRK2 KO mice. Synapsin I level
remains does not differ between the two genotypes.
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